Xortx announces re-filing of ye 2023 and q2 2024 md&a

Calgary, alberta, sept. 12, 2024 (globe newswire) --  xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has refiled its management's discussion and analysis (“md&a”) for the financial year ended december 31, 2023 and for the interim period ended june 30, 2024 as a result of a continuous disclosure review by the alberta securities commission.
XRTX Ratings Summary
XRTX Quant Ranking